


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Currently Amended) A compound of formula I



in which radicals wherein R¹, R², R³, R⁴ and R⁵ as well as R¹⁵ and R¹⁶ have the following meaning:

R¹ is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR⁵, whereby wherein R⁵ is a hydrogen atom, an alkyl or acyl radical with which comprises 1-10 carbon atoms in each case, or an alkylaryl or aralkyl radical with which comprises 6-10 carbon atoms in each case,

R² is a halogen atom or a CF₃ group,

R³ is a hydrogen atom or a group CH₂X, in which wherein X stands for is a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X stands for is a radical (CH₂)_nCH₂Y with wherein n = 0 or 1, and Y stands for is a halogen atom, whereby wherein if R² is a halogen atom, R³ in addition can mean optionally is additionally a group C_nF_mH_o, whereby wherein n = 1, 2, 3, 4 or 5, m > 1 and m + o = 2n + 1,

R⁴ means is a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical with which comprises 6-10 carbon atoms or a radical -CONHR⁵, whereby wherein R⁵ has the above-indicated meaning,

and

R^{15} and R^{16} represent are each, independently of one another, hydrogen atoms or together a double bond.

Claim 2. (Currently Amended) A compound of formula 1 according to claim 1, in which wherein R^2 is a chlorine or bromine atom.

Claim 3. (Currently Amended) A compound of formula I according to claim 1, in which wherein R^3 is a hydrogen atom or a group CH_2X ,

in which X is a hydrogen atom, a hydroxy group, a halogen atom, or a straight-chain or branched or unsaturated alkyl radical with 1-2 carbon atoms, a radical $(CH_2)_nCH_2Y$ with wherein n = 0 or 1, and Y is a halogen atom.

Claim 4. (Previously Presented) A compound of formula I, according to claim 1, wherein R^4 is a hydrogen atom or an alkyl radical with 1 to 4 carbon atoms.

Claim 5. (Currently Amended) A compound of formula I according to claim 1, in which R^1 means is a hydrogen atom, R^2 stands for is a chlorine atom or a bromine atom, and R^3 can be is a hydrogen atom, a methyl group, or a CH_2-X group, whereby wherein X stands for is a fluorine, chlorine or bromine atom or a hydroxy group.

Claim 6. (Currently Amended) A compound of formula I, according to claim 1, which is:

4-[4'-Bromo-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 β -hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 β -hydroxy-17 α -trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[17 β -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[17 β -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-O-acetyloxime,

4-[4'-Chloro-17 β -hydroxy-17 α -trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 α -fluoromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 α -chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 α -bromomethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 β -methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,


4-[4'-Chloro-17 α -chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[17 β -Methoxy-4'-trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime, or

4-[4'-Chloro-17 β -hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime[.].

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of formula I according to claim 1 and a pharmaceutically compatible vehicle.

Claim 8. (Currently Amended) A method for female birth control, for treating dysfunctional bleeding, for treating dysmenorrhea, for inducing an amenorrhea, or for treating hormonal disorders in postmenopausal women, comprising administering to a female a compound of formula I'



in which radicals wherein R¹, R², R³, R⁴ and R⁵ as well as R¹⁵ and R¹⁶ have the following meaning:

R¹ is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR⁵, whereby wherein R⁵ is a hydrogen atom, an alkyl or acyl radical with which comprises 1-10 carbon atoms in each case, or an alkylaryl or aralkyl radical with which comprises 6-10 carbon atoms in each case,

R² is a halogen atom or a CF₃ group,

R³ is a hydrogen atom or a group CH₂X, in which wherein
X stands for is a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical
with 1 or 2 carbon atoms, or X stands for is a radical (CH₂)_nCH₂Y with wherein n =
0 or 1, and Y stands for is a halogen atom,

whereby wherein if R² is a halogen atom, R³ in addition can mean optionally is
additionally a group C_nF_mH_o, whereby wherein n = 1, 2, 3, 4 or 5, m > 1 and m + o
= 2n + 1,

R⁴ means is a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon
atoms in each case or a benzoyl radical with which comprises 6-10 carbon atoms or
a radical -CONHR⁵, whereby wherein R⁵ has the above-indicated meaning,

and

R¹⁵ and R¹⁶ represent are each, independently of one another, hydrogen atoms or together a
double bond.

Claim 9. (Previously Presented) A method for treating dysfunctional bleeding according to
claim 8, comprising administering to a host in need thereof a compound of formula I'.

Claim 10. (Previously Presented) A method for treating dysmenorrhea according to claim 8,
comprising administering to a host in need thereof a compound of formula I'.

Claim 11. (Previously Presented) A method for inducing an amenorrhea according to claim 8,
comprising administering to a host in need thereof a compound of formula I'.

Claim 12. (Previously Presented) A method for treating hormonal disorders in postmenopausal
women according to claim 8, comprising administering to a host in need thereof a compound of
formula I'.

Claim 13. (Previously Presented) A process for treating endometriosis or uterus myomatoses,
comprising administering to a host in need thereof a compound of claim 1.

Claim 14. (Previously Presented) A method according to claim 8, wherein the compound is
administered in combination with at least one low-dose natural or synthetic estrogen.

Claim 15. (Previously Presented) A method according to claim 14, comprising using an estrogen as its 3-sulfamate.

Claim 16. (Previously Presented) A method according to claim 15, wherein the estrogen-3-sulfamate is 17 β -hydroxy-estr-1,3,5(10)-trien-3yl-sulfamate.

Claim 17. (Previously Presented) A method for the production of a pharmacological agent, comprising bringing together a compound of claim 1 and a pharmacologically acceptable carrier.

Claim 18. (Previously Presented) A method for female birth control, comprising administering to a female a compound according to claim 1.


Claim 19. (Previously Presented) A method according to claim 18, wherein the compound is administered in combination with at least one low-dose natural or synthetic estrogen.

Claim 20. (Previously Presented) A method according to claim 19, comprising using an estrogen as its 3-sulfamate.

Claim 21. (Previously Presented) A method according to claim 13, wherein the compound is administered in combination with at least one low-dose natural or synthetic estrogen.

Claim 22. (Previously Presented) A method according to claim 21, comprising using an estrogen as its 3-sulfamate.

Claim 23. (New) A compound of formula I



wherein R¹, R², R³, R⁴ and R⁵ as well as R¹⁵ and R¹⁶ have the following meaning:

R¹ is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR⁵, wherein R⁵ is a hydrogen atom, an alkyl or acyl radical which comprises 1-10 carbon atoms in each case, or an alkylaryl or aralkyl radical which comprises 6-10 carbon atoms in each case,

R² is a halogen atom or a CF₃ group,

R³ is a hydrogen atom or a group CH₂X, wherein

X is a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X is a radical (CH₂)_nCH₂Y wherein n = 0 or 1, and Y is a halogen atom,

wherein if R² is a halogen atom, R³ optionally is additionally a group C_nF_mH_o, wherein n = 1, 2, 3, 4 or 5, m > 1 and m + o = 2n + 1,

R⁴ is a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical which comprises 6-10 carbon atoms or a radical –CONHR⁵, wherein R⁵ has the above-indicated meaning,

and

R¹⁵ and R¹⁶ are each, independently of one another, hydrogen or together a double bond, or a pharmaceutically acceptable salt thereof.

Claim 24. (New)

A method for female birth control, for treating dysfunctional bleeding, for treating dysmenorrhea, for inducing an amenorrhea, or for treating hormonal disorders in postmenopausal women, comprising administering to a female a compound according to claim 23,